GW&K Investment Management LLC cut its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 2.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 341,673 shares of the specialty pharmaceutical company’s stock after selling 8,994 shares during the quarter. GW&K Investment Management LLC owned 0.53% of Jazz Pharmaceuticals worth $79,105,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Private Advisor Group LLC increased its stake in Jazz Pharmaceuticals by 193.2% in the 3rd quarter. Private Advisor Group LLC now owns 3,046 shares of the specialty pharmaceutical company’s stock worth $705,000 after purchasing an additional 2,007 shares during the period. Ieq Capital LLC grew its stake in shares of Jazz Pharmaceuticals by 1,149.2% in the third quarter. Ieq Capital LLC now owns 20,625 shares of the specialty pharmaceutical company’s stock worth $4,775,000 after acquiring an additional 18,974 shares during the last quarter. Focus Advisor Solutions LLC raised its holdings in Jazz Pharmaceuticals by 75.2% in the 3rd quarter. Focus Advisor Solutions LLC now owns 2,802 shares of the specialty pharmaceutical company’s stock worth $649,000 after acquiring an additional 1,203 shares during the last quarter. Edgestream Partners L.P. purchased a new position in Jazz Pharmaceuticals in the 3rd quarter worth about $302,000. Finally, HighTower Advisors LLC boosted its holdings in Jazz Pharmaceuticals by 6.9% in the third quarter. HighTower Advisors LLC now owns 7,268 shares of the specialty pharmaceutical company’s stock worth $1,683,000 after purchasing an additional 471 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research analysts have recently weighed in on the stock. Sanford C. Bernstein reiterated a “market perform” rating and set a $220.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, November 9th. Needham & Company LLC boosted their target price on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Canaccord Genuity Group set a $300.00 price target on Jazz Pharmaceuticals in a report on Wednesday, August 26th. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a report on Thursday, September 24th. They issued a “buy” rating and a $337.00 target price on the stock. Finally, Wall Street Zen lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $294.25.
Get Our Latest Stock Report on JAZZ
Insider Activity
In other news, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total transaction of $289,128.00. Following the transaction, the executive vice president directly owned 47,671 shares in the company, valued at approximately $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renee D. Gala sold 2,000 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $243.03, for a total transaction of $486,060.00. Following the sale, the chief executive officer owned 143,394 shares of the company’s stock, valued at approximately $34,849,043.82. This represents a 1.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 171,342 shares of company stock worth $41,420,491 over the last ninety days. 4.10% of the stock is owned by corporate insiders.
Jazz Pharmaceuticals Trading Down 4.7%
Shares of Jazz Pharmaceuticals stock opened at $236.22 on Friday. The stock has a market cap of $15.16 billion, a PE ratio of 21.97, a price-to-earnings-growth ratio of 0.45 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 1 year low of $156.95 and a 1 year high of $266.38. The firm has a fifty day moving average price of $229.05 and a 200 day moving average price of $221.14. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.82 and a quick ratio of 1.64.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same period in the previous year, the company earned $8.13 EPS. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. Equities research analysts predict that Jazz Pharmaceuticals PLC will post 11.18 earnings per share for the current year.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.
Recommended Stories
- Five stocks we like better than Jazz Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
